Takeda's Hopes For Replacement Diabetes Drug May Hit U.S. FDA Wall
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's SYR-322 (alogliptin) diabetes drug, which it was relying on to take the place of one of its best-sellers, may be headed for a four-year delay in getting U.S. FDA approval. The drug maker faces the possibility of having to conduct more clinical trials to determine the drug's contribution to the risk of heart attacks and strokes. An FDA decision on whether to require the tests is considered imminent. Takeda was counting on the drug to be on the market in time to cushion losses when its Actos (pioglitazone) diabetes drug loses U.S. patent protection. (Click here for more
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.